Phaseline

Companies › Neurona Therapeutics

Neurona Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Neurology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NRTX-1001
GABA-secreting GABAergic interneurons derived from human embryonic stem cells
GABAPhase 3Mesial Temporal Lobe Epilepsy; Epilepsy, Temporal LobeJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06422923NRTX-1001Phase 1Epilepsy, Temporal LobeNeurologyJun 2027
NCT05135091NRTX-1001Phase 3Mesial Temporal Lobe EpilepsyNeurologyFeb 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GABA (1)

Companies with the same targets

PleoPharma Aelis Farma

Companies built like this

Sandoz Merz Pharmaceuticals Lupin Cytopeutics Sdn. Bhd. NKGen Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.